dc.contributor.author
Pallarés Giner, Roman
dc.contributor.author
Liñares Louzao, Josefina
dc.contributor.author
Vadillo, Miquel
dc.contributor.author
Cabellos Mínguez, Ma. Carmen
dc.contributor.author
Manresa, Federico
dc.contributor.author
Viladrich, Pedro F.
dc.contributor.author
Martín, Rogelio
dc.contributor.author
Gudiol i Munté, Francesc
dc.date.issued
2018-05-29T06:54:49Z
dc.date.issued
2018-05-29T06:54:49Z
dc.date.issued
1995-08-24
dc.date.issued
2018-05-29T06:54:50Z
dc.identifier
https://hdl.handle.net/2445/122614
dc.description.abstract
Background: Penicillin-resistant strains of Streptococcus pneumoniae are now found worldwide, and strains with resistance to cephalosporin are being reported. The appropriate antibiotic therapy for pneumococcal pneumonia due to resistant strains remains controversial. Methods: To examine the effect of resistance to penicillin and cephalosporin on mortality, we conducted a 10-year, prospective study in Barcelona of 504 adults with culture-proved pneumococcal pneumonia. Results: Among the 504 patients, 145 (29 percent) had penicillin-resistant strains of S. pneumoniae (minimal inhibitory concentration [MIC] of penicillin G, 0.12 to 4.0 μg per milliliter), and 31 patients (6 percent) had cephalosporin-resistant strains (MIC of ceftriaxone or cefotaxime, 1.0 to 4.0 μg per milliliter). Mortality was 38 percent in patients with penicillin-resistant strains, as compared with 24 percent in patients with penicillin-sensitive strains (P = 0.001). However, after the exclusion of patients with polymicrobial pneumonia and adjustment for other predictors of mortality, the odds ratio for mortality in patients with penicillin-resistant strains was 1.0 (95 percent confidence interval, 0.5 to 1.9; P = 0.84). Among patients treated with penicillin G or ampicillin, the mortality was 25 percent in the 24 with penicillin-resistant strains and 19 percent in the 126 with penicillin-sensitive strains (P = 0.51). Among patients treated with ceftriaxone or cefotaxime, the mortality was 22 percent in the 59 with penicillin-resistant strains and 25 percent in the 127 with penicillin-sensitive strains (P = 0.64). The frequency of resistance to cephalosporin increased from 2 percent in 1984-1988 to 9 percent in 1989-1993 (P = 0.002). Mortality was 26 percent in patients with cephalosporin-resistant S. pneumoniae and 28 percent in patients with susceptible organisms (P = 0.89). Among patients treated with ceftriaxone or cefotaxime, mortality was 22 percent in the 18 with cephalosporin-resistant strains and 24 percent in the 168 with cephalosporin-sensitive organisms (P = 0.64). Conclusions: Current levels of resistance to penicillin and cephalosporin by S. pneumoniae are not associated with increased mortality in patients with pneumococcal pneumonia. Hence, these antibiotics remain the therapy of choice for this disease.
dc.format
application/pdf
dc.publisher
Massachusetts Medical Society
dc.relation
Reproducció del document publicat a: https://doi.org/10.1056/NEJM199508243330802
dc.relation
New England Journal of Medicine, 1995, vol. 333, num. 8, p. 474-480
dc.relation
https://doi.org/10.1056/NEJM199508243330802
dc.rights
(c) Massachusetts Medical Society, 1995
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Ciències Clíniques)
dc.subject
Cefalosporines
dc.subject
Medicaments antibacterians
dc.subject
Barcelona (Catalunya)
dc.subject
Cephalosporines
dc.subject
Antibacterial agents
dc.title
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion